<DOC>
	<DOCNO>NCT01752075</DOCNO>
	<brief_summary>The REVLIMID Registry provide safety data large cohort Taiwanese patient treat REVLIMID . In addition , registry provide efficacy data outcomes real-world setting ( versus clinical trial ) .</brief_summary>
	<brief_title>A Non-interventional , Observational Post-marketing Registry Patients Treated With Revlimid ( Lenalidomide ) Taiwan</brief_title>
	<detailed_description>The REVLIMID Registry prospective , multi-center , observational study . The registry register 100 patient prescribe REVLIMID Taiwan patient follow two year enrollment last patient . Safety efficacy data record registry monthly bi-monthly . In accordance Risk Minimization Program REVLIMID ( RevAssure ) patient categorize woman childbearing potential prescribe REVLIMID monthly basis , whereas woman non-childbearing potential men allow two month supply per prescription . After entry baseline data , prescribe physician prescribe monitor REVLIMID therapy accord guidance recommend schedule give approve Taiwan package insert ( PI )</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Adult patient 18 year age old Patients prescribe REVLIMID combination dexamethasone treatment multiple myeloma receive least one prior therapy Patient must willing able provide inform consent Patients inform Registry sign specific Registry Informed Consent Form Be able ask question prior sign Subject Information Consent Form Be clearly inform involvement/participation registry voluntary Understand medical care alter way participation registry A Patient unwilling unable provide inform consent include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Multiple myeloma</keyword>
</DOC>